The results of this study suggest that enhancing the catabolic effect of NPY-ergic Y2 receptors may open up potential new ways to treat obesity without any adverse effects on cortical bone mass, the major determinant of bone strength. This evidence concerns the gene NPY and obesity due to melanocortin 4 receptor deficiency.